Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome

American Journal of Medicine

Volumn 103, Issue 1, 1997, Pages 38-43

  Vollmer Conna, Ute ^a   Hickie, Ian ^b   Hadzi Pavlovic, Dusan ^b   Tymms, Kathie ^c   Wakefield, Denis ^a,b   Dwyer, John ^b   Lloyd, Andrew ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE HENRY HOSPITAL   (Australia)

^c WODEN VALLEY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN; PLACEBO;

ADULT; ARTICLE; CELLULAR IMMUNITY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MOOD; PHLEBITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030873395     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)90045-0     Document Type: Article

References (26)

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaraff A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953-959.
2. Hickie I, Lloyd A, Hadzi-Pavlovic D, Parker G, Bird K, Wakefield D. Can the chronic fatigue syndrome be defined by distinct clinical features? Psychol Med. 1995;25:925-935.
3. Lloyd A, Pender H. The economic impact of chronic fatigue syndrome. Med J Aust. 1992;157:599-601.
4. Wilson A, Hickie I, Lloyd A, Wakefield D. Science and speculation: the treatment of chronic fatigue syndrome. Am J Med. 1994;96:544-550.
5. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with the chronic fatigue syndrome. Am J Med. 1990;89:561-568.
6. Peterson PK, Shepard J, Macres M, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med. 1990;89:554-560.
7. Behan PO, Behan WMH, Bell EJ. The postviral fatigue syndrome - analysis of the findings in 50 cases. J Infect. 1985;10:211-222.
8. Straus S. The chronic mononucleosis syndrome. J Infect Dis. 1988;157: 405-412.
9. White PD, Thomas JM, Amess J, Graver SA, Kangro HO, Clare AW. The existence of a fatigue syndrome after glandular fever. Psychol Med. 1995; 25:907-916.
10. White PD, Grover SA, Kangro HO, Thomas JM, Amess J, Clare AW. The validity and reliability of the fatigue syndrome which follows glandular fever. Psychol Med. 1995;25:917-924.
11. Wakefield D, Lloyd A. Pathophysiology of myalgic encephalomyelitis. Lancet. 1987;ii:918-919.
12. Lloyd A, Hickie I, Hickie C, Dwyer J, Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression, Clin Exp lmmunol. 1992;87:76-79.
13. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403-1410.
14. Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: Clinical condition associated with immune activation. Lancet. 1991;338: 707-712.
15. Lloyd A, Hickie I, Wakefield D. Immunity and the pathophysiology of chronic fatigue syndrome. Ciba Foundation Symposium. 1993;173:176-192.
16. Dwyer JM. Intravenous therapy with gamma globulin. Adv Intern Med. 1987;32:111-136.
17. Straus SE. Intravenous immunoglobulin treatment for the chronic fatigue syndrome. Am J Med. 1990;89:551-552.
18. Lloyd A, Hickie I, Boughton CR, Spencer O, Wakefield D. The prevalence of chronic fatigue syndrome in an Australian population. Med J Aust. 1990: 153:522-528.
19. Schluederberg A, Straus SE, Peterson P, et al. Chronic fatigue syndrome research: definition and medical outcome assessment. Ann Intern Med. 1992; 117:325-331.
20. Karnofsky D, Abelmann W, Graver L, Burchenal J. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-656.
21. Gill W. Monitoring the subjective well-being of chronically ill patients over time. Community Health Stud. 1984;8:288-297.
22. McNair DM, Lorr M, Droppleman LF. Profile of Mood States: Manual. San Diego, California: Educational and industrial testing service, 1981.
23. Jackson AL, Warner NL. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, (eds.). Manual of Clinical Laboratory Immunology. Washington DC: American Soc. for Microbiology 1986;226-235.
24. Kniker W, Anderson C, McBryde J, Roumiantzeff M, Lesourd B. Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cell-mediated immunity. Normal values and proposed scoring system for healthy adults in the USA. Ann Allergy. 1984;52:75-82.
25. Lloyd AR, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, Wakefield D. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: A double-blind, placebo-controlled trial. Am J Med. 1993;94:197-203.
26. Wilson A, Hickie I, Lloyd A, et al. Longitudinal study of outcome of chronic fatigue syndrome. BMJ 1994;308:756-759.